《中国药房》杂志药物经济学评价研究文献分析  

Bibliometric Analysis of Pharmacoeconomic Evaluation Literatures Published on Journal of China Pharmacy

作　　者：曾力楠[1,2] 梁毅[1,2] 胡蝶[1,2] 张伶俐[1] 

机构地区：[1]四川大学华西第二医院药剂科,成都市610041 [2]四川大学华西药学院,成都市610041

出　　处：《中国药房》2011年第22期2019-2022,共4页China Pharmacy

摘　　要：目的:评估《中国药房》杂志发表的药物经济学研究文献的质量及主要研究内容。方法:检索1990-2009年《中国药房》杂志发表的药物经济学评价研究文献,根据药物经济学评价研究质量评价标准,评价纳入研究质量,并分析纳入研究所涉及的人群、疾病及干预措施种类。结果:获得研究文献202篇,首篇于1997年发表。主要研究单位为医疗机构,共涉及15类疾病,以不同种(类)药物干预措施间的经济性比较为主。与我国居民主要疾病死亡率对照显示,部分疾病负担较重的领域尚缺乏药物经济学研究。多数研究目的与研究角度不明确,研究分析方法单一。结论:药物经济学评价研究的方法学质量尚需提高。OBJECTIVE： To evaluate the methodological quality and contents of pharmacoeconomic evaluation literatures published on Journal of China Pharmacy. METHODS： We searched pharmacoeconomic evaluation literatures published on Journal of China Pharmacy from 1990 to 2009. According to pharmacoeconomic evaluation criteria, the quality of included studies was evaluated. The population, disease and intervention measures involved in study were studied. RESULTS： 202 pharmacoeconomic evaluation literatures were included. The first literature was published on 1997. Medical institute contributed most of these studies. These studies regarded 15 kinds of disease in a whole and mainly conducted economical comparison among different types of medicines. Contrasting with the mortality of main disease of resident in China, some fields with relative heavy disease burden lacked pharmacoeconomic study. The methodological quality of included studies was limited： lack of clear aim, no research perspective, single research method. CONCLUSION： The methodological quality of included studies should be further improved.

关 键 词：中国药房杂志 药物经济学 文献计量分析 

分 类 号：R956[医药卫生—药学]